Related Experiment Video

Updated: Dec 10, 2025

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

23.4K

Pediatric SJS-TEN: Where are we now?

Michele Ramien1,2, Jennifer L Goldman3,4

  • 1Department of Pediatrics, University of Calgary, Alberta Children's Hospital, 28 Oki Dr NW, Calgary, AB, Canada.

F1000Research
|August 28, 2020
PubMed

Insights

Stevens-Johnson syndrome and toxic epidermal necrolysis are severe skin reactions. Recent advances improve diagnosis and management, including identifying Mycoplasma pneumoniae as a cause in some cases.

Area of Science:

  • Dermatology
  • Pediatrics
  • Pharmacology

Background:

  • Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, severe mucocutaneous reactions.
  • These conditions are often triggered by medications or infections.
  • Recent research has significantly advanced the understanding of SJS/TEN.

Purpose of the Study:

  • To provide an update on pediatric SJS and TEN.
  • To discuss SJS/TEN within the context of cutaneous adverse drug reactions.
  • To highlight recent advances and challenges in diagnosis, management, and prevention.

Main Methods:

  • Review of recent scientific literature on SJS/TEN.
  • Focus on pediatric cases and Mycoplasma pneumoniae-induced rash and mucositis (MIRM).
  • Analysis of diagnostic, therapeutic, and preventive strategies.

Main Results:

  • Identification of MIRM as a distinct entity in SJS/TEN.
  • Advances in understanding disease mechanisms and treatment responses.
  • Recognition of challenges in early diagnosis and management.

Conclusions:

  • A revised diagnostic paradigm is needed, considering infectious triggers like Mycoplasma pneumoniae.
  • Continued research is crucial for improving outcomes in pediatric SJS/TEN.
  • Multidisciplinary approaches enhance patient care for severe cutaneous reactions.

Keywords:
DENRIMESJSStevens-Johnson syndromeTENdrug eruptiondrug reactiondrug-induced epidermal necrolysisreactive infectious mucocutaneous eruptionsevere cutaneous drug reactiontoxic epidermal necrolysis

More Related Videos

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.6K
A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
147
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
172
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
108
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
148
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
315